Evidence map›Paper›PMID 38537326›Full record

ArticleTranslational oncology2024

A regionally based precision medicine implementation initiative in North Africa:The PerMediNA consortium.

Yosr Hamdi, Maroua Boujemaa, Jihenne Ben Aissa-Haj, Fouzia Radouani, Meriem Khyatti, Najah Mighri, Mariem Hannachi, Kais Ghedira, Oussema Souiai, Chaima Hkimi and 15 more

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 5 countries.

Yosr HamdiLaboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia. Electronic address: yosr.hamdi@pasteur.utm.tn.
Maroua BoujemaaLaboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Jihenne Ben Aissa-HajLaboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia; Department of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis 1002, Tunisia.
Fouzia RadouaniChlamydiae and Mycoplasmas Laboratory, Research Department, Institut Pasteur du Maroc, Casablanca, Morocco.
Meriem KhyattiLaboratory of Viral Oncology, Institut Pasteur du Maroc, Casablanca, Morocco.
Najah MighriLaboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Mariem HannachiLaboratory of Bioinformatics, Biomathematics and Biostatistics LR20IPT09, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Kais GhediraLaboratory of Bioinformatics, Biomathematics and Biostatistics LR20IPT09, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Oussema SouiaiLaboratory of Bioinformatics, Biomathematics and Biostatistics LR20IPT09, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Chaima HkimiLaboratory of Bioinformatics, Biomathematics and Biostatistics LR20IPT09, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Mohamed Selim KammounLaboratory of Bioinformatics, Biomathematics and Biostatistics LR20IPT09, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Nesrine MejriLaboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia; Medical Oncology Department, Abderrahmane Mami Hospital, Faculty of Medicine, University Tunis El Manar, Tunis, Tunisia.
Hanen BouazizLaboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia; Department of Carcinological Surgery, Salah Azaiez Institute, Tunis, Tunisia.
Mohamed Amine BeloufaVirology Department, Institut pasteur d'Algérie, Algeria.
Hicham CharouteResearch unit of Epidemiology, Biostatistics and Bioinformatics, Institut Pasteur du Maroc, Casablanca, Morocco.
Abdelhamid BarakatLaboratory of Genomics and Human Genetics, Institut Pasteur du Maroc 20360, Casablanca, Morocco.
Imène NajjarBiomics, Center for Technological Resources and Research (C2RT), Institut Pasteur, Paris 75015, France.
Hiroaki TaniguchiThe Polish Academy of Sciences, Poland; University Mohamed VI, Morocco.
Natalia PietrosemoliInstitut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub F-75015, Paris, France.
PerMediNA Consortium
Koussay DellagiPasteur Network Association, Institut Pasteur, Paris, France.
Sonia AbdelhakLaboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Mohamed Samir BoubakerLaboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia; Department of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis 1002, Tunisia.
Claudia ChicaInstitut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub F-75015, Paris, France.
Etienne RouleauDepartment of Biology and Pathology-Cancer Genetics Laboratory-Gustave Roussy 94805, Villejuif, France.
Tunis University · TNInstitut Pasteur du Maroc · MAInstitut Pasteur · FRInstitut Pasteur d'Algérie · DZInstitut Gustave Roussy · FRInstitut Pasteur de Tunis · TNMohamed I University · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precision Medicine is being increasingly used in the developed world to improve health care. While several Precision Medicine (PM) initiatives have been launched worldwide, their implementations have proven to be more challenging particularly in low- and middle-income countries. To address this issue, the "Personalized Medicine in North Africa" initiative (PerMediNA) was launched in three North African countries namely Tunisia, Algeria and Morocco. PerMediNA is coordinated by Institut Pasteur de Tunis together with the French Ministry for Europe and Foreign Affairs, with the support of Institut Pasteur in France. The project is carried out along with Institut Pasteur d'Algérie and Institut Pasteur du Maroc in collaboration with national and international leading institutions in the field of PM including Institut Gustave Roussy in Paris. PerMediNA aims to assess the readiness level of PM implementation in North Africa, to strengthen PM infrastructure, to provide workforce training, to generate genomic data on North African populations, to implement cost effective, affordable and sustainable genetic testing for cancer patients and to inform policy makers on how to translate research knowledge into health products and services. Gender equity and involvement of young scientists in this implementation process are other key goals of the PerMediNA project. In this paper, we are describing PerMediNA as the first PM implementation initiative in North Africa. Such initiatives contribute significantly in shortening existing health disparities and inequities between developed and developing countries and accelerate access to innovative treatments for global health.

Indexed as

Affordable genetic testingCapacity buildingEquityNorth AfricaPrecision medicine

Identifiers

PMID38537326
PMCPMC11391035
OpenAlexW4393180064

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.